Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JBJ-04-125-02 + Naquotinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JBJ-04-125-02 | JBJ-04-125-02 is a next-generation allosteric EGFR inhibitor, which selectively inhibits the kinase activity and activation of EGFR L858R, resulting in reduced cell proliferation, increased apoptosis and tumor growth inhibition (PMID: 31092401). | |||
Naquotinib | ASP8273 | AXL Inhibitor 30 EGFR Inhibitor 3rd gen 26 | Naquotinib (ASP8273) is a third-generation EGFR inhibitor that binds mutant forms of EGFR, including T790M, and also inhibits AXL, thus may lead to growth inhibition in tumor cells (PMID: 29467275, PMID: 31092564). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|